Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, ROC.
Eur J Pharmacol. 2011 Sep 30;667(1-3):292-7. doi: 10.1016/j.ejphar.2011.05.062. Epub 2011 Jun 2.
Nicorandil is an adenosine triphosphate-sensitive potassium channel opener that combines an organic nitrate and a nicotinamide group which respectively confer to nicorandil the additional properties of being a nitric oxide (NO) donor and antioxidant; it also induces vasodilation, decreases the blood pressure, and protects the heart. However, the intracellular mechanism of nicorandil remains to be delineated. The aims of this study were to test the hypothesis that nicorandil alters strain-induced endothelin-1 secretion and NO production, and to identify the putative underlying signaling pathways in human umbilical vein endothelial cells (HUVECs). Cultured HUVECs were exposed to cyclic strain in the presence of nicorandil; endothelin-1 expression was examined by reverse-transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay. Activation of extracellular signal-regulated protein kinase (ERK), endothelial NO synthase (eNOS), and activating transcription factor (ATF)-3 was assessed by Western blot analysis. We show that nicorandil inhibited strain-induced endothelin-1 expression. Nicorandil also inhibited strain-increased reactive oxygen species formation and ERK phosphorylation. On the contrary, NO production, eNOS phosphorylation, and ATF3 expression were enhanced by nicorandil; however, L-NAME (an inhibitor of eNOS) and LY294002 (an inhibitor of phosphatidylinositol 3-kinase) inhibited nicorandil-increased ATF3 expression. Moreover, treatment of HUVECs with either an NO donor (NOC18; 3,3-bis[aminoethyl]-1-hydroxy-2-oxo-1-triazene) or an ATF3 activator (MG-132; carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) resulted in repression of strain-induced endothelin-1 expression. Furthermore, L-NAME, and small interfering RNA transfection of eNOS also partially attenuated the inhibitory effect of nicorandil on strain-induced endothelin-1 expression. We demonstrate for the first time that nicorandil inhibits strain-induced endothelin-1 secretion via an increase in NO and upregulation of ATF3 in HUVECs. This study provides important new insights into the molecular pathways that may contribute to the beneficial effects of nicorandil in the cardiovascular system.
尼可地尔是一种三磷酸腺苷敏感性钾通道开放剂,它结合了有机硝酸盐和烟酰胺基团,分别赋予尼可地尔作为一氧化氮 (NO) 供体和抗氧化剂的额外特性;它还诱导血管扩张、降低血压并保护心脏。然而,尼可地尔的细胞内机制仍有待阐明。本研究旨在验证尼可地尔改变应变诱导的内皮素-1 分泌和 NO 产生的假设,并鉴定人脐静脉内皮细胞 (HUVEC) 中潜在的信号通路。在存在尼可地尔的情况下,将培养的 HUVEC 暴露于环应变下;通过逆转录-聚合酶链反应和酶联免疫吸附试验检查内皮素-1 的表达。通过 Western blot 分析评估细胞外信号调节蛋白激酶 (ERK)、内皮型一氧化氮合酶 (eNOS) 和激活转录因子 (ATF)-3 的激活。我们表明尼可地尔抑制应变诱导的内皮素-1 表达。尼可地尔还抑制应变增加的活性氧形成和 ERK 磷酸化。相反,尼可地尔增强了 NO 产生、eNOS 磷酸化和 ATF3 表达;然而,L-NAME(eNOS 抑制剂)和 LY294002(PI3K 抑制剂)抑制了尼可地尔增加的 ATF3 表达。此外,用 NO 供体 (NOC18;3,3-双[氨基乙基]-1-羟基-2-氧代-1-三嗪)或 ATF3 激活剂 (MG-132;苯甲酰基-L-亮氨酰-L-亮氨酰-L-亮氨酸)处理 HUVECs 可抑制应变诱导的内皮素-1 表达。此外,L-NAME 和 eNOS 的小干扰 RNA 转染也部分减弱了尼可地尔对应变诱导的内皮素-1 表达的抑制作用。我们首次证明,尼可地尔通过增加 HUVEC 中的 NO 和上调 ATF3 来抑制应变诱导的内皮素-1 分泌。这项研究为尼可地尔在心血管系统中有益作用的分子途径提供了重要的新见解。